The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO

被引：12

作者：

Di Cosimo, S. ^{[1
]}

Campbell, C. ^{[2
]}

Azim, H. A., Jr. ^{[3
]}

Galli, G. ^{[1
]}

Bregni, G. ^{[4
]}

Curigliano, G. ^{[5
]}

Criscitiello, C. ^{[5
]}

Izquierdo, M. ^{[6
]}

de la Pena, L. ^{[7
]}

Fumagalli, D. ^{[8
]}

Fein, L. ^{[9
]}

Vinholes, J. ^{[10
]}

Ng, W. M. J. ^{[11
]}

Colleoni, M. ^{[12
]}

Ferro, A. ^{[13
]}

Naume, B. J. ^{[14
]}

Patel, A. ^{[15
]}

Huober, J. ^{[16
]}

Piccart-Gebhart, M. J. ^{[3
]}

Baselga, J. ^{[17
]}

de Azambuja, E. ^{[3
]}

机构：

[1] Ist Nazl Tumori Milano, Fdn IRCCS, Milan, Italy

[2] Frontier Sci Scotland Ltd, Kincraig, Scotland

[3] ULB, Inst Jules Bordet, Brussels, Belgium

[4] IRCCS AOU S Martino IST, Genoa, Italy

[5] European Inst Oncol, Milan, Italy

[6] Novartis Pharma AG, Basel, Switzerland

[7] SOLTI Breast Canc Res Grp, Barcelona, Spain

[8] Breast Int Grp, Brussels, Belgium

[9] Inst Oncol Rosario, Rosario, Santa Fe, Argentina

[10] Clin Oncol, Porto Alegre, RS, Brazil

[11] Queen Elizabeth Hosp, Hong Kong, Hong Kong, Peoples R China

[12] Ist Europeo Oncol, Milan, Italy

[13] Osped Trento, Trento, Italy

[14] Oslo Univ Hosp, Oslo, Norway

[15] Princess Alexandra Hosp NHS Trust, Harlow, Essex, England

[16] Ulm Univ Hosp, Ulm, Germany

[17] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

来源：

EUROPEAN JOURNAL OF CANCER | 2018年 / 89卷

关键词：

HER2 positive breast cancer; Targeted therapy; Neoadjuvant; Mammography; Breast ultrasound; PATHOLOGICAL COMPLETE RESPONSE; OPEN-LABEL; PHASE-3; TRIAL; TUMOR SIZE; CHEMOTHERAPY; ACCURACY; SURVIVAL; MULTICENTER; MAMMOGRAPHY; SAFETY;

D O I：

10.1016/j.ejca.2017.10.036

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: To determine the value of mammography and breast ultrasound (US) in predicting outcomes in HER2 positive breast cancer patients (pts) within Neo-ALTTO trial. Patients and methods: Mammography and US were required at baseline, week 6 and surgery. Two independent blinded investigators reviewed the measurements and assigned the corresponding response category. Pts showing complete or partial response according to RECIST (v1.1) were classified as responders. The association between imaging response at week 6 or prior to surgery was evaluated with respect to pathological complete response (pCR) and event-free Survival (EFS). Results: Of the 455 pts enrolled in the trial, 267 (61%) and 340 (77%) had evaluable mammography and US at week 6; 248 (56%) and 309 (70%) pts had evaluable mammography and US prior to surgery. At week 6, 32% and 43% of pts were classified as responders by mammography and US, respectively. pCR rates were twice as high for responders than non-responders (week 6: 46% versus 23% by US, p < 0.0001; 41% versus 24% by mammography, p = 0.007). Positive and negative predictive values of mammography and US prior to surgery were 37% and 35%, and 82% and 70%, respectively. No significant correlation was found between response by mammography and/or US at week 6/surgery and EFS. Conclusions: Mammography and US were underused in Neo-ALTTO although US had the potential to assess early response whereas mammography to detect residual disease prior to surgery. Our data still emphasise the need for further imaging studies on pts treated with neoadjuvant HER2-targeted therapy. (C) 2017 Elsevier Ltd. All rights reserved.

引用

页码：42 / 48

页数：7

共 27 条

[1] Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule [J].

Baselga, J ;

Carbonell, X ;

Castañeda-Soto, NJ ;

Clemens, M ;

Green, M ;

Harvey, V ;

Morales, S ;

Barton, C ;

Ghahramani, P .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (10) :2162-2171

[2] Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial [J].

Baselga, Jose ;

Bradbury, Ian ;

Eidtmann, Holger ;

Di Cosimo, Serena ;

de Azambuja, Evandro ;

Aura, Claudia ;

Gomez, Henry ;

Dinh, Phuong ;

Fauria, Karine ;

Van Dooren, Veerle ;

Aktan, Gursel ;

Goldhirsch, Aron ;

Chang, Tsai-Wang ;

Horvath, Zsolt ;

Coccia-Portugal, Maria ;

Domont, Julien ;

Tseng, Ling-Min ;

Kunz, Georg ;

Sohn, Joo Hyuk ;

Semiglazov, Vladimir ;

Lerzo, Guillermo ;

Palacova, Marketa ;

Probachai, Volodymyr ;

Pusztai, Lajos ;

Untch, Michael ;

Gelber, Richard D. ;

Piccart-Gebhart, Martine .

LANCET, 2012, 379 (9816) :633-640

[3] Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer [J].

Berg, WA ;

Gutierrez, L ;

NessAiver, MS ;

Carter, WB ;

Bhargavan, M ;

Lewis, RS ;

Ioffe, OB .

RADIOLOGY, 2004, 233 (03) :830-849

[4] Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas [J].

Burris, HA ;

Hurwitz, HI ;

Dees, EC ;

Dowlati, A ;

Blackwell, KL ;

O'Neil, B ;

Marcom, PK ;

Ellis, MJ ;

Overmoyer, B ;

Jones, SF ;

Harris, JL ;

Smith, DA ;

Koch, KM ;

Stead, A ;

Mangum, S ;

Spector, NL .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) :5305-5313

[5] Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy [J].

Chagpar, AB ;

Middleton, LP ;

Sahin, AA ;

Dempsey, P ;

Buzdar, AU ;

Mirza, AN ;

Ames, FC ;

Babiera, GV ;

Feig, BW ;

Hunt, KK ;

Kuerer, HM ;

Meric-Bernstam, F ;

Ross, MI ;

Singletary, SE .

ANNALS OF SURGERY, 2006, 243 (02) :257-264

[6] Direct comparison of PET/CT and MRI to predict the pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis [J].

Chen, Lihua ;

Yang, Qifang ;

Bao, Jing ;

Liu, Daihong ;

Huang, Xuequan ;

Wang, Jian .

SCIENTIFIC REPORTS, 2017, 7

[7] Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response [J].

de Azambuja, Evandro ;

Holmes, Andrew P. ;

Piccart-Gebhart, Martine ;

Holmes, Eileen ;

Di Cosimo, Serena ;

Swaby, Ramona F. ;

Untch, Michael ;

Jackisch, Christian ;

Lang, Istvan ;

Smith, Ian ;

Boyle, Frances ;

Xu, Binghe ;

Barrios, Carlos H. ;

Perez, Edith A. ;

Azim, Hatem A., Jr. ;

Kim, Sung-Bae ;

Kuemmel, Sherko ;

Huang, Chiun-Sheng ;

Vuylsteke, Peter ;

Hsieh, Ruey-Kuen ;

Gorbunova, Vera ;

Eniu, Alexandru ;

Dreosti, Lydia ;

Tavartkiladze, Natalia ;

Gelber, Richard D. ;

Eidtmann, Holger ;

Baselga, Jose .

LANCET ONCOLOGY, 2014, 15 (10) :1137-1146

[8] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[9] 18F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO [J].

Gebhart, Geraldine ;

Gamez, Cristina ;

Holmes, Eileen ;

Robles, Javier ;

Garcia, Camilo ;

Cortes, Montserrat ;

de Azambuja, Evandro ;

Fauria, Karine ;

Van Dooren, Veerle ;

Aktan, Gursel ;

Coccia-Portugal, Maria Antonia ;

Kim, Sung-Bae ;

Vuylsteke, Peter ;

Cure, Herve ;

Eidtmann, Holger ;

Baselga, Jose ;

Piccart, Martine ;

Flamen, Patrick ;

Di Cosimo, Serena .

JOURNAL OF NUCLEAR MEDICINE, 2013, 54 (11) :1862-1868

[10] 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial [J].

Gianni, Luca ;

Pienkowski, Tadeusz ;

Im, Young-Hyuck ;

Tseng, Ling-Ming ;

Liu, Mei-Ching ;

Lluch, Ana ;

Staroslawska, Elzbieta ;

de la Haba-Rodriguez, Juan ;

Im, Seock-Ah ;

Pedrini, Jose Luiz ;

Poirier, Brigitte ;

Morandi, Paolo ;

Semiglazov, Vladimir ;

Srimuninnimit, Vichien ;

Bianchi, Giulia Valeria ;

Magazzu, Domenico ;

McNally, Virginia ;

Douthwaite, Hannah ;

Ross, Graham ;

Valagussa, Pinuccia .

LANCET ONCOLOGY, 2016, 17 (06) :791-800

← 1 2 3 →